# Inno Medicine

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inno-medicine

- Industry: Pharmaceuticals
- Headquarters: Beijing, China
- Website: www.innovmedicine.com
- Total disclosed funding: $119M
- Latest round: Series D (Sep 8, 2026)
- Investors on record: 11

## About

Based in Beijing, China and founded in 2016, Beijing Inno Medicine Co., Ltd., dba Inno Medicine, is a pharmaceutical company engaged in the research, development, and manufacturing of novel, precision-targeted drugs. The company has a production base in Shanghai. Qian Ma, the company's founder and CEO, is an expert physician at Beijing Anzhen Hospital Affiliated to Capital Medical University. In 2024, "YN002", the company's pipeline for identifying high risk plaque obtained FDA IND approval.

In September 2026, Inno Medicine raised approximately CNY 800 million in Series D funding led by YuanBio Venture with participation from Shunxi Fund, Beijing Jingguorui Equity Investment Fund Management, CoStone Capital, Chengtong Science, Technology Innovation, Credito Capital, Gaorong Ventures, NLVC, Zhongqi  Capital, Renhe Capital and Chunjia Capital, and from other investors.

Inno Medicine focuses on targeted drugs, having developed multiple pipelines including "YN001" for the treatment of atherosclerotic cardiovascular disease (ASCVD), "YN002" for identifying high risk plaque, and "YN003" for the treatment of glioma and brain metastasis. 

The company generates revenue by providing targeted drugs in the fields of cardiovascular and tumor.

The company will primarily use the Series D funding for international multi-center clinical trials of its core pipeline products, further accelerating its global clinical development and commercialization.

## Funding rounds

- Series D, Sep 8, 2026, $119M — NLVC, CoStone Capital, Gaorong Ventures, YuanBio Venture, Renhe Capital, Chunjia Capital, Credito Capital, Beijing Jingguorui Equity Investment Fund Management, Shunxi Fund, Zhongqi  Capital, Chengtong Science and Technology Innovation

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series D
- CoStone Capital (https://capitalatlas.ai/funds/costone-capital) — Series D
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series D
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series D
- Renhe Capital (https://capitalatlas.ai/funds/renhe-capital) — Series D
- Chunjia Capital (https://capitalatlas.ai/funds/chunjia-capital) — Series D
- Credito Capital (https://capitalatlas.ai/funds/credito-capital) — Series D
- Beijing Jingguorui Equity Investment Fund Management (https://capitalatlas.ai/funds/beijing-jingguorui-equity-investment-fund-management) — Series D
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series D
- Zhongqi  Capital (https://capitalatlas.ai/funds/zhongqi-capital) — Series D
- Chengtong Science and Technology Innovation (https://capitalatlas.ai/funds/chengtong-science-and-technology-innovation) — Series D